Get started
Credo Technology Group (CRDO) – Powering the AI Data Center BoomCompany Snapshot: Credo Technology NASDAQ:CRDO is a rising star in AI infrastructure, delivering high-speed, low-power connectivity solutions that are mission-critical to modern data centers. Key Catalysts: AI Infrastructure Tailwinds 🧠🏢 Direct exposure to Active Electrical Cables (AEC) and PCIe retimers Positioned for rapid demand acceleration from AI, cloud, and hyperscale data centers AEC chip market expected to grow 15x from $68M (2023) to $1B+ by 2028 Sticky Software + Hardware Model 🧩 PILOT software platform offers real-time diagnostics and performance tuning Enables a recurring revenue model and strengthens customer retention Scalable, Energy-Efficient Portfolio ⚡🌐 High-bandwidth, low-power design aligns with sustainability goals of large data centers Integrated solutions are already seeing early adoption momentum Investment Outlook: ✅ Bullish Above: $51.00–$52.00 🚀 Upside Target: $90.00–$92.00 📈 Growth Drivers: AI infrastructure demand, software expansion, chip market scale 💡 Credo isn’t just riding the AI wave—it’s building the rails for it. #CRDO #AIInfrastructure #Semiconductors
NASDAQ:CRDOLong
by Richtv_official
MSGS – Technical Setup + Long-Term OpportunityTaking a swing long here on Madison Square Garden Sports Corp. ( NYSE:MSGS ). Price just pulled back into the Ichimoku cloud with support at the base line, offering a high-probability bounce setup. Risk/reward looks solid at 3.82 with a target of $219–$223 and a tight stop near $183. Why MSGS? 🎟️ Owns the Knicks & Rangers – both cash machines in a media-driven era. 🧾 Clean balance sheet, low debt, and real estate-backed value. 💰 No dividend, but serious potential for buybacks and long-term appreciation. 🧠 Analysts see hidden value in MSGS due to the brand/IP strength and optionality with sports media rights. Indicators MACD just crossed bearish, but price hasn't confirmed downside. Watching for bull divergence and recovery within the cloud. Weekly support still holding; a reclaim of the $195 level confirms bullish continuation. 🧠 Thesis: If MSGS gets back above $200, momentum could drive it to $220+. Happy to hold as a value/growth hybrid anchored by real-world assets.
NYSE:MSGSLong
by aaronkaltman
BILL Long Setup – 39.57% Upside PotentialWatching NYSE:BILL for a potential breakout play. The price is holding just under the cloud with a clean base forming. If we push through the cloud, this could trigger a strong move toward the $62–63 zone — aligning with the top of the previous range and pivot zone. 📈 Setup Details: Entry: $45.03 Stop: $44.04 (tight 2.2%) Target: $62.97 R/R Ratio: 17.9 Indicators: Ichimoku Cloud + trend compression + inside support zone Volume remains steady and we’ve rejected lower prices multiple times — a breakout above the cloud could confirm buyer strength. 🎯 Trade Thesis: Low-risk, high-reward breakout setup with tight stop and strong upside if macro sentiment holds. Watching for confirmation above cloud + key volume levels.
NYSE:BILLLong
by aaronkaltman
IBM: Bullish AttemptsIBM has made progress in our scenario: Currently, the price is rising above the crucial resistance at $265.72; clearly surpassing this mark is important in the ongoing wave (3) in magenta. While we cannot entirely remove our alternative scenario with a new low for wave alt. in green, it still holds a 33% probability. We primarily expect that the regular wave in green was already completed at $211.52 and are therefore preparing for a direct continuation of the increases in the broader wave in green. 📈 Over 190 precise analyses, clear entry points, and defined Target Zones - that's what we do.
NYSE:IBMLong
by MarketIntel
Trendline Breakout - SPARCCurrent Price: ₹169.82 Technical Analysis: Trendline Breakout Pattern: This is a bullish technical signal. A breakout from a trendline, especially if it was a resistance trendline, suggests that the stock has overcome a significant hurdle and is likely to move higher. For confirmation, it's ideal to see the breakout accompanied by strong trading volume. Immediate Target: ₹233 Time Frame: 3 to 6 months (This suggests a medium-term horizon for achieving the target). Fundamental Analysis: Company Overview: SPARC is a pharmaceutical company engaged in research and development. It's important to note that R&D-focused companies often have different financial profiles compared to established, revenue-generating pharmaceutical companies. They typically have lower or even negative profits in the short term as they invest heavily in developing new drugs and technologies. Quarterly Results (Q4 FY25 - ended March 31, 2025): SPARC often reports losses due to its R&D heavy nature. For Q4 FY25, the company reported a consolidated net loss of ₹90.3 crore, higher than the loss of ₹60.8 crore in Q4 FY24. Revenue from operations also declined to ₹40.5 crore in Q4 FY25 from ₹51.4 crore in Q4 FY24. Yearly Results (FY25 - ended March 31, 2025): For the full fiscal year FY25, SPARC reported a consolidated net loss of ₹363.8 crore, significantly higher than the loss of ₹237.3 crore in FY24. Revenue from operations for FY25 also decreased to ₹182.2 crore from ₹236.8 crore in FY24. P/E Ratio: Given that SPARC often reports losses, its P/E ratio is typically not applicable (N/A) or negative, as a P/E ratio requires positive earnings. Investors usually evaluate such companies based on factors like pipeline progress, clinical trial results, regulatory approvals, and potential market size of their innovations rather than traditional profitability metrics. EPS Comparison: As the company is often in a loss-making phase due to R&D expenses, the EPS is typically negative. Comparing negative EPS values can be less insightful than tracking the progress of their drug pipeline. Corporate Actions: Dividend: SPARC typically does not pay dividends given its R&D phase and often negative profitability. Funding/Partnerships: Key corporate actions for SPARC would include fundraising rounds, strategic partnerships for drug development or commercialization, and announcements related to regulatory approvals or clinical trial successes. Company Order Book: SPARC, being an R&D company, generally does not have a traditional "order book" like manufacturing or infrastructure companies. Its future revenue visibility depends on successful drug development, licensing agreements, or commercialization of its patented products. Latest News: Q4 and FY25 Results: The latest news would likely focus on the company's increased losses and decreased revenue, along with management commentary on the progress of their various drug candidates in clinical trials. Clinical Trial Updates: Any announcements regarding the phases of clinical trials (Phase I, II, III), interim results, or regulatory submissions for its drug pipeline would be significant news. Research & Development: Updates on new research areas or technological advancements. Overall Assessment: SPARC presents a challenging fundamental picture with consistent losses and declining revenue, typical of an R&D-heavy pharmaceutical firm. Investors in SPARC are essentially betting on the future success of its drug pipeline. The Trendline Breakout pattern identified in your technical analysis suggests that the stock might be building momentum. If the market is anticipating a positive development (e.g., successful trial results, regulatory approval) that could fundamentally change its profitability, then the technical breakout might be a leading indicator. The immediate target of ₹233 would represent a significant upside. However, it is crucial to understand that for a company like SPARC, technical breakouts can be highly speculative without a corresponding positive fundamental catalyst related to its drug development pipeline. The stock's movement is heavily dependent on news flow regarding its R&D projects. Key Factors to Monitor: Confirmation of Technical Breakout: Ensure the breakout is sustained with strong volume. R&D Pipeline Progress: This is paramount. Track updates on their drug candidates, clinical trial results, and regulatory milestones. Cash Burn Rate: Given its losses, monitor the company's cash position and burn rate. Strategic Partnerships: Any new collaborations could provide funding and validation for its research. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Investing in R&D-focused pharmaceutical companies like SPARC carries inherently high risks due to the uncertainty of drug development and regulatory approvals. Always conduct your own thorough research, understand the company's drug pipeline, assess your risk tolerance, and consult with a qualified financial advisor before making any investment decisions.
NSE:SPARCLong
by sara54654
MercadoLibre Inc Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # MercadoLibre Inc Stock Quote - Double Formation * (Upper Band)) #1 - *4% Settings Condition | Completed Survey * Entry & Retest At 0.5 Retracement Area | Subdivision 1 - Triple Formation * (EMA Settings)) * 100 EMA - *Support & Resistance | Subdivision 2 * (TP1) | Subdivision 3 * Daily Time Frame | Trend Settings Condition - (Hypothesis On Entry Bias)) | Indexed To 100 - Position On A 1.5RR * Stop Loss At 156.00 USD * Entry At 165.00 USD * Take Profit At 180.00 USD * (Ranging Argument)) & No Pattern Confirmation * Ongoing Entry & (Neutral Area)) Active Sessions On Relevant Range & Elemented Probabilities; European-Session(Upwards) - East Coast-Session(Downwards) - Asian-Session(Ranging) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Buy
PEPPERSTONE:MELILong
by TradePolitics
Retro Editors' picks 2020As we move forward through time, we occasionally must look backward to evaluate our progress and address our shortcomings. For years, PineCoders has voluntarily analyzed numerous published scripts, selecting the most exceptional among them as Editors' picks . To enhance our process and spotlight more high-quality work from our community, we've conducted a comprehensive review of script publications from the past five years. Through this effort, we've identified several additional scripts that deserve greater recognition than they initially received. Below is a collection of additional scripts from 2020 that have earned a spot in our Editors' picks. These retrospective selections reflect our continued commitment to honoring outstanding contributions in our community, regardless of when they were published. To the authors of these highlighted scripts: our sincere thanks, on behalf of all TradingViewers. Congrats! Support Resistance Channels - LonesomeTheBlue BERLIN Candles - lejmer Delta Volume Columns Pro - LucF Range Filter - DonovanWall Over the next four months, in the last week of each month, we will share retro Editors' picks for subsequent years: June: retro EPs for 2021 July: retro EPs for 2022 August: retro EPs for 2023 September: retro EPs for 2024 They will be visible in the Editors' picks feed . █   What are Editors' picks ? The Editors' picks showcase the best open-source script publications selected by our PineCoders team. Many of these scripts are original and only available on TradingView. These picks are not recommendations to buy or sell anything or use a specific indicator. We aim to highlight the most interesting publications to encourage learning and sharing in our community. Any open-source script publication in the Community Scripts can be picked if it is original, provides good potential value to traders, includes a helpful description, and complies with the House Rules. — The PineCoders team
SWB:SQ6BEducation
by PineCoders
9
MSFT Breaking out? 4 Things Need to be Fixed FirstIn the last 2 weeks, MSFT broke above 2 major pivot levels $448 and $455 – that’s just 4 weeks after hitting a 52-week low on April 7th Some would say that this represents huge momentum – and that the stock is ready for a major breakout above all-time high level and fly above $470 I have 4 issues with that view – that I need the stock to go through first and “prove itself” – let’s take a look at them quickly 1. Daily Shows Exhaustion: The last few daily bars are not reflecting confidence in the price moves – they reflect exhaustion – that’s almost all last week – the price struggled to close at the day’s high. 2. Missing the Right Alignment: The 50SMA is still below the 100SMA – that shows the bulls will still need a “breather” to consolidate their efforts and the key SMAs to align properly. In the daily view we also see how extended the price is (look at the purple line 20SMA wrt the other MA's) 3. Over-bought Weekly: The weekly chart shows the stock as over-bought, supporting the view that some profit taking and consolidation need to happen first before a serious breakout to new highs 4. Unsupportive Market: The market is still not recovered – we’re still in “daily-news-jumpy-sensitive” mode – there are even opinions that we’re in a bear market rally. Then some large money are waiting to see the outcome of tariffs and other decisions that will have lagging impact in June & July .. for me this is the most critical factor. MSFT continues to be one of the best plays out there, so as we build up the position in our portfolio, let’s keep an eye on these factors and await setups with higher probabilities. As usual, this is not a trading recommendation - just my own quick analysis - please feel free to share your thoughts.
NASDAQ:MSFTLong
by RedKTrader
RELIANCE: Strong Resistance at ₹1600 — Covered Call Setup📉 Chart Context: Reliance recently rallied ~25% from lows near ₹1,150 to ₹1,450. The rally stalled at the broken lower trendline of a long-term channel, turning resistance. Price action now showing rejection around ₹1,435–₹1,450 zone — a historical supply area. 📊 Derivatives Insight: July ₹1600 CE has the highest Open Interest across the chain: 3.6 lakh+ contracts. This strike acts as a clear ceiling for market participants. IV for ₹1600 CE is elevated at 21.8%, indicating overpricing of far OTM risk. 📈 Strategy: Strategy Bias: Neutral / Mildly Bearish ⚠️ Note: This strategy is suitable only for investors already holding a sizeable position (≥500 shares) in Reliance. It is not a recommendation to buy the stock solely for option writing. With 500+ shares held, this aligns perfectly for a covered call: Sell July ₹1600 CE at ₹7.20 Generate passive income (~₹3,600/lot) while capping gains ~13% above CMP Play on sideways or weakening structure without exiting core position ⚠️ Risk Management: If Reliance breaches ₹1600 before expiry, gains above this are capped Position sizing and pledge margin must be managed correctly 📌 Conclusion: This is a textbook low-risk income strategy using technical resistance, OI data, and IV edge. Unless a fresh breakout emerges, ₹1600 stands firm. Disclaimer: T his analysis is for educational and informational purposes only. It does not constitute investment advice or a recommendation. Options trading involves risk. Always do your own research or consult a financial advisor before making decisions.
NSE:RELIANCE
by eggubonda
Nampak is packing great upside to R561It's been the underdog for a while now. WHich the price just moving sideways since late 2024. But now it's had a major breakout to the upside. What's causing it, I'm not sure but we can suspect a few things. 1. Debt Restructuring Complete Nampak finalized its debt renegotiation, easing investor fears of default. 2. Improved Cash Flow Asset sales and cost cuts have strengthened free cash flow. 3. Packaging Demand Rebound Recovery in the FMCG and beverage sectors boosts demand for cans and packaging. 4. Undervalued Stock The share trades well below book value, attracting value investors. And the technicals look great. W Formation Price above 20 and 200 Target R579.61
JSE:NPKLong
by Timonrosso